Adverse events of modern antifungal drugs during treatment of invasive fungal infections

Adverse events of modern antifungal drugs during treatment of invasive fungal infections

Characteristics of adverse events of modern antimycotics by organ systems and comparative frequency between different medicines and their groups are presented. The examples of incompatibility of antifungal drugs with other pharmacological groups are discussed. Records of adverse events and drug comp...

Full description

Saved in:

Bibliographic Details
Main Authors:	N. V. Dmitrieva, I. N. Petukhova
Format:	Article
Language:	Russian
Published:	ABV-press 2014-07-01
Series:	Онкогематология
Subjects:	amphothericin b azoles echinocandins adverse events
Online Access:	https://oncohematology.abvpress.ru/ongm/article/view/34
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Clinical Features, Outcomes, and Antifungal Susceptibility Profiles of Invasive Candida Infections in a Tertiary Care Hospital in China
by: Yao D, et al.
Published: (2025-05-01)

In vitro susceptibility profiles of 16 antifungal drugs against Trichophyton indotineae
by: Wenting Xie, et al.
Published: (2025-08-01)

Reviewing the mechanism of action and results of clinical studies on the antifungal drug ibrexafungerp
by: L. I. Tagirova, et al.
Published: (2024-05-01)

Research progress on the drug resistance mechanisms of Candida tropicalis and future solutions
by: Huisheng Xiong, et al.
Published: (2025-05-01)

Core histones govern echinocandin susceptibility in Candida glabrata
by: Aditi Pareek, et al.
Published: (2025-06-01)

<i>Candida glabrata</i> Prosthetic Joint Infection Managed with Ibrexafungerp
by: Ella Nadarevic, et al.
Published: (2025-06-01)

Tn-seq screens in Candida glabrata treated with echinocandins and ibrexafungerp reveal pathways of antifungal resistance and cross-resistance
by: Timothy J. Nickels, et al.
Published: (2025-07-01)

Invasive candidiasis in children
by: N. N. Klimko, et al.
Published: (2021-07-01)

ADVERSE EVENT OF DRUG THERAPY (THE FIRST RESULTS OF THE STUDY ACCORDING TO THE PROFILE OUTPATIENT REGISTER)
by: Yu. V. Lukina, et al.
Published: (2016-06-01)

Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals
by: José Luis Arredondo-García, et al.
Published: (2009-06-01)

Efficacy and safety of triazoles versus echinocandins in the treatment of invasive aspergillosis: A meta-analysis
by: Uzelac Sanja M., et al.
Published: (2020-01-01)

Adverse event reporting following immunization of hepatitis B vaccine: A 13-year review
by: Xiaoying Gong, et al.
Published: (2024-12-01)

Fungal infections in humans: the silent crisis
by: Katharina Kainz, et al.
Published: (2020-06-01)

Three aspects of acupuncture-related adverse events: Issues around the reporting of acupuncture-related adverse events
by: Tae-Hun Kim, et al.
Published: (2023-09-01)

Pharmacovigilance study of famciclovir in the Food and Drug administration adverse event reporting system database
by: Runan Fang, et al.
Published: (2024-11-01)

Adverse events associated with gepants: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Qi Song, et al.
Published: (2025-06-01)

Analysis of Adverse Events Associated With Dental Local Anaesthetics Using Food and Drug Administration Adverse Event Reporting System Data
by: Ferit Bayram, et al.
Published: (2025-06-01)

Real-world study of adverse events associated with triptan use in migraine treatment based on the U.S. Food and Drug Administration (FDA) adverse event reporting system (FAERS) database
by: Wen-Hui Liu, et al.
Published: (2024-11-01)

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System
by: Hang Chen, et al.
Published: (2025-06-01)

A post-marketing pharmacovigilance study of triazole antifungals: adverse event data mining and analysis based on the FDA adverse event reporting system database
by: Yalan Tian, et al.
Published: (2025-01-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

Modern methods of identification of adverse events associated with medication errors
by: A. P. Pereverzev, et al.
Published: (2018-02-01)

Safety assessment of ripretinib: a real-world adverse event analysis from the food and drug administration adverse event reporting system
by: Sentai Wang, et al.
Published: (2025-03-01)

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-01-01)

Magnitude and Characteristics of Adverse Drug Events in Saudi Arabia: A Systematic Review
by: Lina Alharbi, et al.
Published: (2025-04-01)

Adverse event profile differences between maribavir and valganciclovir: findings from the FDA adverse event reporting system
by: Haolin Teng, et al.
Published: (2025-05-01)

Corrigendum: Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database
by: Xi-Feng Wang, et al.
Published: (2025-02-01)

Comprehensive analysis of adverse events associated with vortioxetine using the FDA adverse event reporting system
by: Liangxia Li, et al.
Published: (2025-05-01)

Descriptive analysis of the national drug adverse events (AEs) database in Lebanon
by: Rita Karam, et al.
Published: (2025-12-01)

Occurrence and predictors of adverse events associated with linezolid in the treatment of patients with drug resistant tuberculosis and their impact on treatment outcomes
by: Abhirami V, et al.
Published: (2025-06-01)

Updated insights into adverse events associated with mepolizumab: a disproportionality analysis from the FDA adverse event reporting system database
by: Shan Lin, et al.
Published: (2024-10-01)

Surveillance for adverse events following immunization in Hebei Province, China, 2018-2020
by: Li Sun, et al.
Published: (2024-12-01)

Possible Association Between Concomitant Use of SSRIs with NSAIDs and an Increased Risk of Adverse Events Among People with Depressive Disorders: Data Mining of FDA Adverse Event Reporting System
by: Yi Zhang, et al.
Published: (2025-07-01)

Comparative efficacy and tolerability of amphotericin B lipid complex and liposomal amphotericin B in the treatment of invasive fungal infections in patients with hematological malignancies: literature review
by: N. V. Dmitrieva, et al.
Published: (2014-07-01)

ICD-10 Codes to Identify Adverse Drug Events Associated with Antibiotics in Administrative Data
by: Hannah Lishman, et al.
Published: (2025-03-01)

Adverse events in the neonatal intensive care unit identified by triggers
by: Fabiana Bragança Albanese, et al.
Published: (2025-05-01)

Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database
by: Chang-Zhu He, et al.
Published: (2025-03-01)

Improved Sixty-Day Mortality in Candidemia with Antifungal Treatment Within 72 Hours of Fever Onset: A Single-Center Retrospective Study in Rural Japan
by: Koji Hayashi, et al.
Published: (2025-04-01)

TO DISCONTINUE OR TO WAIT?: INDICATIONS FOR DISCONTINUATION OF ANTI-TUBERCULOSIS DRUGS DUE TO ADVERSE EVENTS
by: D. A. Ivаnovа, et al.
Published: (2018-03-01)

DARE-SAFE: Denominator-Adjusted Rate Estimates of Substance Adverse Events Frequency Evaluation in Pharmaceuticals and Vaccines
by: Matthew Halma, et al.
Published: (2025-03-01)